EAU-EANM-ESTRO-ESUR-SIOG前列腺癌指南2020更新第二部分:复发性和转移性前列腺癌的治疗
该指南由EAU联合EANM、ESTRO、ESUR、SIOG制定,基于2016-2019年文献综述更新,涵盖生化复发、转移性激素敏感及去势抵抗性前列腺癌的治疗推荐。PSMA PET/CT在生化复发中作用增强,根治性前列腺切除术后早期挽救放疗与辅助放疗效果相当,并新增多种转移性前列腺癌治疗选择及低瘤负荷转移性激素敏感患者局部放疗的作用。
要点
- PSMA PET/CT在生化复发患者中的作用日益重要。
- 根治性前列腺切除术后早期挽救放疗与辅助放疗效果相当,部分患者应联合雄激素剥夺治疗。
- 转移性激素敏感、非转移性CRPC及转移性CRPC出现新治疗选择,低瘤负荷转移性激素敏感患者可考虑局部放疗。
核心结论
- 晚期及转移性前列腺癌和CRPC领域知识快速变化,2020版指南汇总最新证据并为临床实践提供建议。
研究设计与样本
- 工作组对2016-2019年新数据进行文献综述,基于系统评价更新指南并添加证据级别和/或推荐等级。
主要发现
- PSMA PET/CT扫描在局部治疗后生化复发男性中的作用日益重要。
- 根治性前列腺切除术后早期挽救放疗与辅助放疗效果相当,在部分患者中应联合雄激素剥夺治疗。
- 转移性激素敏感前列腺癌、非转移性CRPC和转移性CRPC出现新治疗选择。
- 低瘤负荷转移性激素敏感前列腺癌男性中局部放疗具有一定作用。
- 指南还纳入了前列腺癌患者生活质量结局的信息。
临床怎么用
- 指南为循证医学基础,指导临床医生与患者讨论治疗决策。
- 指南每年更新,本摘要涵盖2017-2020年新证据期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2016-2019). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature. EVIDENCE SYNTHESIS: Prostate-specific membrane antigen positron emission tomography computed tomography scanning has developed an increasingly important role in men with biochemical recurrence after local therapy. Early salvage radiotherapy after radical prostatectomy appears as effective as adjuvant radiotherapy and, in a subset of patients, should be combined with androgen deprivation. New treatments have become available for men with metastatic hormone-sensitive prostate cancer (PCa), nonmetastatic CRPC, and metastatic CRPC, along with a role for local radiotherapy in men with low-volume metastatic hormone-sensitive PCa. Also included is information on quality of life outcomes in men with PCa. CONCLUSIONS: The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/). PATIENT SUMMARY: This article summarises the guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are evidence based and guide the clinician in the discussion with the patient on the treatment decisions to be taken. These guidelines are updated every year; this summary spans the 2017-2020 period of new evidence.
引用
- Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020. PMID: 33039206. doi:10.1016/j.eururo.2020.09.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。